Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

This study is testing a drug called HQP1351 (olverembatinib) for people with chronic myeloid leukemia (CML) or a type of acute lymphoblastic leukemia driven by the Philadelphia chromosome, whose cancer has stopped responding to or cannot tolerate other treatments, including those with a hard-to-treat mutation called T315I. **You may be eligible if:** - You have CML in any phase (chronic, accelerated, or blast) or Ph+ ALL - You have tried and failed or cannot tolerate at least two prior TKI (targeted) drugs - If you have a T315I mutation, the number of prior treatments is not restricted **You may NOT be eligible if:** - You have not tried prior TKI therapies (unless you have a T315I mutation with specific exceptions) - You have severe organ problems or other conditions making this treatment unsafe - You are pregnant or not using appropriate contraception Talk to your doctor to see if this trial is right for you.